xenograft experiments with GBM cell lines engineered to express either TF or EGFRvIII oncogene. RESULTS: Expression of coagulation factors (coagulome) is subtype-specific in GBM and TF expression correlates with the classical subtype. Inhibition of TF modulates EGFRvIII-driven growth of GBM xenografts. GBM-related human cells undergo tumor dormancy in a manner influenced by tissue factor (TF) expression. Thus, indolent, TF-deficient subline of human glioma, U373, forms viable, but permanently dormant deposits at the injection site. Expression of TF in these cells leads to a stepwise transition to latent and overt tumor growth phases, and this process that is associated with recruitment of vascular (CD105+) and myeloid (CD11b+ and F4/80+) elements. Importantly, the microenvironment orchestrated by TF expression facilitates permanent secondary changes in the phenotype, gene expression profile, DNA copy number and DNA methylation state of tumor cells that escaped from dormancy. CONCLUSIONS: We postulate that there is a degree of specificity in activation of the coagulation system by GBM subtypes driven by defined oncogenic pathways. Thus, TF is regulated by EGFRdependent transformation. Conversely, we also suggest that procoagulant events in the tissue microenvironment (niche) may affect the fate of occult tumor cells, including biological and genetic progression to a full blown GBM-like malignancy. SECONDARY CATEGORY: Preclinical Experimental Therapeutics. Neuro-Oncology 16:iii1 -iii22, 2014 . doi:10.1093 
